European pharmaceutical contract development and manufacturing organization (CDMO) NextPharma is all set to acquire Santen’s manufacturing facility in Tampere, Finland. The takeover is expected to be completed in the summer of 2019.
NextPharma will be overlooking the production of Santen products at the Tampere manufacturing facility as a part of the strategic alliance between the two countries. NextPharma will be acquiring the facility with the complete staff employed at the unit. Currently, a total of 181 employees work at Santen’s manufacturing facility and the whole staff including quality assurance, quality control, IT and administration will be transferred over to NextPharma.
However, the acquisition will not impact other Santen employees whose job roles are not linked with manufacturing in any way. The employees that fall under the category include people from IT, human resources, sales and marketing, and R&D.
Santen’s alliance with NextPharma is a part of its strategy to expand its presence in the global marketplace. The pharmaceuticals company plans to leverage NextPharma’s resources to streamline its supply chain and continue advances in the field of ophthalmology and blow fill seal technology. Santen expects to achieve sustainable growth under NextPharma’s extensive pharmaceutical manufacturing network and establish itself as a strong global player in the market.
On the other hand, the acquisition of the Santen site is an important development for NextPharma who are continuously expanding their manufacturing network in Europe. Santen will become NextPharma’s seventh manufacturing site in Europe with the other six facilities specializing in different therapeutic drugs and medical technologies.
NextPharma provides a complete range of pharmaceutical businesses which covers almost every vertical involved in the production of pharmaceuticals. It provides services across the supply chain, pharmaceutical development and licensing, clinical trial services, manufacturing and packaging, and analytical services. The company’s manufacturing units serve multiple clients around the world and produce a variety of common and specialized drugs.